Postoperative circulating tumor DNA detection predicts recurrence and guides adjuvant chemotherapy duration in high-risk stage III colorectal cancer

Figure 2 Kaplan-Meier analysis of recurrence-free survival according to postoperative circulating tumor DNA status and adjuvant chemotherapy duration. A: Kaplan-Meier curves for recurrence-free survival (RFS) stratified by postoperative circulating tumor DNA (ctDNA) status. The curves represent ctDNA-positive and ctDNA-negative patients (Log-rank P = 0.026); B: Kaplan-Meier curves for RFS in ctDNA-positive patients stratified by chemotherapy duration. The curves represent the 3-month and 6-month capecitabine plus oxaliplatin (CapOX) chemotherapy subgroups (Log-rank P = 0.689); C: Kaplan-Meier curves for RFS in ctDNA-negative patients stratified by chemotherapy duration. The legend represents the 3-month and 6-month CapOX chemotherapy subgroups (Log-rank P = 0.512); D: Kaplan-Meier curves for RFS comparing ctDNA-positive patients receiving 3 months of CapOX chemotherapy and ctDNA-negative patients receiving 6 months of CapOX chemotherapy (Log-rank P = 0.038). ctDNA: Circulating tumor DNA; CapoX: Capecitabine plus oxaliplatin.